Mizuho initiated coverage of Enliven Therapeutics with a Buy rating and $34 price target. The company has validated biology, differentiated chemistry and disciplined trial design to bring new life to standards of care, the analyst telsl investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELVN:
- Enliven to share initial proof of concept data from ELVN-001 Phase 1 trial
- Enliven Therapeutics to Share Initial Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 and Host Virtual Key Opinion Leader Event on April 11, 2024
- Enliven Therapeutics Secures $90M for Clinical Research Expansion
- Enliven announces pipeline updates
- Enliven announces $90M private placement financing